Business Wire

Quit Like Sweden Urges Progressive Tobacco Control to Save Millions of Lives on World No Tobacco Day

Share

Millions of lives could be saved with a more progressive approach to tobacco control measures, says a new platform committed to encouraging countries to follow the Swedish Experience and become ‘smoke-free’. As the world gears up to observe World No Tobacco Day (WNTD) on May 31, Quit Like Sweden, launched earlier this year in Brazil, is calling for proven strategies to enhance the global fight against smoking.

Traditionally, WNTD has been marked exclusively by calls for the complete abandonment of smoking. However, Quit Like Sweden argues that it's time for policymakers, regulators, governments, the media, and the general public to engage in a meaningful discussion about the strategies that do reduce the devastating impacts of smoking and smoking-related illnesses.

Suely Castro, Founder of Quit Like Sweden, emphasized the need for a new approach, citing the Swedish Experience and remarkable progress in tobacco control.

"Each World No Tobacco Day, the international community argues that a world without cigarettes is the ultimate aim. But this World No Tobacco Day, instead of discussing what could be possible, it’s time to look at what is already being done by the only country that is close to quitting smoking: Sweden," said Suely Castro.

While Sweden has rigorously adopted smoking cessation and prevention measures, it has also enabled smokers to choose safer alternatives. This approach, based on what Ms Castro calls the three A's – which stand for the Accessibility, Acceptability, and Affordability of safer alternatives – has resulted in millions of Swedes choosing to leave cigarettes behind and switch to safer alternatives.

"In Sweden, one in four adults uses nicotine every day. While this is the same level as the rest of Europe, Sweden’s incidence of cancer is 41% lower, and smoking-related deaths in Sweden are less than half of smoking-related deaths in 24 of the other 26 EU countries”, Castro said.

“This is the case within European countries, which have similar regulations to those of Sweden, although not its comprehensive approach to eradicating smoking. Just imagine what the global impact of the full Swedish Experience could be.”

“We have the ability to save millions of lives just by replicating a model that has already worked so well for Sweden,” she said. "And there’s no better time to start that conversation than now.”

Background

Quit Like Sweden is a not-for-profit platform with the aim to encourage countries to take action to replicate the Swedish Experience in a comprehensive strategy that also includes measures and programmes focused on smoking cessation and prevention, and enabling people who smoke to choose alternatives instead.

We don’t advocate for the removal of measures and programmes that contribute to smoking cessation or prevention, and instead appeal to all policymakers in all countries, intergovernmental and non-governmental organizations to complement those measures and programmes.

Sweden Statistics

As a result of Sweden’s progressive tobacco control measures:

  1. Sweden is the only country in the world to officially be ‘smoke-free’, when its smoking prevalence falls below 5% later this year.
  2. Across Europe, the smoking rate is 5 times higher than Sweden’s.
  3. 24 of the 27 EU countries have a tobacco-related mortality rate at least twice as high as Sweden’s.
  4. Sweden’s incidence of cancer is 41% lower than the rest of Europe’s, which means 38% lower levels of total cancer deaths.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries & Interviews:
Suely Castro, Founder, Quit Like Sweden
suelycastro@quitlikesweden.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye